|Articles|January 12, 2023

Phesi Releases Results of Global Analysis of Clinical Trials Conducted in 2021

Analysis shows breast cancer was the most extensively studied disease area in previous year.

Phesi has released the results of its global analysis of all clinical trials conducted in 2021. The data show that breast cancer was the most studied disease area, followed by COVID-19. Overall, oncology had a strong presence in the top five, which also included non-small cell lung cancer, solid tumors, and multiple myeloma.

Read more about the analysis here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
September 15th 2025
ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025

Trending on Applied Clinical Trials Online

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

Merck Reports Strong Phase II Results for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

© 2025 MJH Life Sciences^®

All rights reserved.